SlideShare una empresa de Scribd logo
1 de 4
Interpreting Hazard
Ratios
Terry Shaneyfelt, MD, MPH
Associate Professor of Medicine
UAB Department of Medicine
ebmteacher.com
• Time-to-event analysis
• Ratio of hazards
• Hazard
– Instantaneous event rate
• Probability that an individual at time t has an event at
that time (assuming event-free survival to time t)
Hazard Ratio
Hazard in treatment arm
Hazard in control arm
HR=
• HR = 1 (event rates are the same in both arms)
• HR = 2 (at any time twice as many patients in
the treatment group are having an event
proportionally to the comparator group)
• HR = 0.5 (at an time half as many patients in the
treatment group are having an event
proportionally to the comparator group)
Interpreting Hazard Ratios
• Often interpreted as a relative risk
– Not technically the same
Interpreting Hazard Ratios
http://cancerguide.org/scurve_basic.html
Lancet 2003;361:1149

Más contenido relacionado

La actualidad más candente

Intent-to-Treat (ITT) Analysis in Randomized Clinical Trials
Intent-to-Treat (ITT) Analysis in Randomized Clinical TrialsIntent-to-Treat (ITT) Analysis in Randomized Clinical Trials
Intent-to-Treat (ITT) Analysis in Randomized Clinical TrialsMike LaValley
 
Basic survival analysis
Basic survival analysisBasic survival analysis
Basic survival analysisMike LaValley
 
What does an odds ratio or relative risk mean?
What does an odds ratio or relative risk mean? What does an odds ratio or relative risk mean?
What does an odds ratio or relative risk mean? Terry Shaneyfelt
 
Relative and Atribute Risk
Relative and Atribute RiskRelative and Atribute Risk
Relative and Atribute RiskTauseef Jawaid
 
Nested case control study
Nested case control studyNested case control study
Nested case control studyPrayas Gautam
 
2. Case study and case series
2. Case study and case series2. Case study and case series
2. Case study and case seriesRazif Shahril
 
Analyzing the randomised control trial (rct)
Analyzing the randomised control trial (rct)Analyzing the randomised control trial (rct)
Analyzing the randomised control trial (rct)Vikash Keshri
 
Attributable risk and population attributable risk
Attributable risk and population attributable riskAttributable risk and population attributable risk
Attributable risk and population attributable riskAbino David
 
Targeted therapy and immunotherapy in lung cancer
Targeted therapy and immunotherapy in lung cancerTargeted therapy and immunotherapy in lung cancer
Targeted therapy and immunotherapy in lung cancerAlok Gupta
 
Efficacy endpoints in Oncology
Efficacy endpoints in OncologyEfficacy endpoints in Oncology
Efficacy endpoints in OncologyAngelo Tinazzi
 
Odds ratios (Basic concepts)
Odds ratios (Basic concepts)Odds ratios (Basic concepts)
Odds ratios (Basic concepts)Tarekk Alazabee
 
Medical Statistics used in Oncology
Medical Statistics used in OncologyMedical Statistics used in Oncology
Medical Statistics used in OncologyNamrata Das
 
Noninferiority Trials Presentation
Noninferiority Trials PresentationNoninferiority Trials Presentation
Noninferiority Trials Presentationhsturgeon
 
Cohort study - basics
Cohort study - basicsCohort study - basics
Cohort study - basicsRizwan S A
 

La actualidad más candente (20)

Intent-to-Treat (ITT) Analysis in Randomized Clinical Trials
Intent-to-Treat (ITT) Analysis in Randomized Clinical TrialsIntent-to-Treat (ITT) Analysis in Randomized Clinical Trials
Intent-to-Treat (ITT) Analysis in Randomized Clinical Trials
 
Basic survival analysis
Basic survival analysisBasic survival analysis
Basic survival analysis
 
What does an odds ratio or relative risk mean?
What does an odds ratio or relative risk mean? What does an odds ratio or relative risk mean?
What does an odds ratio or relative risk mean?
 
Relative and Atribute Risk
Relative and Atribute RiskRelative and Atribute Risk
Relative and Atribute Risk
 
Nested case control study
Nested case control studyNested case control study
Nested case control study
 
Part 1 Survival Analysis
Part 1 Survival AnalysisPart 1 Survival Analysis
Part 1 Survival Analysis
 
2. Case study and case series
2. Case study and case series2. Case study and case series
2. Case study and case series
 
Sample size calculations
Sample size calculationsSample size calculations
Sample size calculations
 
Analyzing the randomised control trial (rct)
Analyzing the randomised control trial (rct)Analyzing the randomised control trial (rct)
Analyzing the randomised control trial (rct)
 
NNT: Number Needed to Treat
NNT: Number Needed to TreatNNT: Number Needed to Treat
NNT: Number Needed to Treat
 
The odds ratio
The odds ratioThe odds ratio
The odds ratio
 
Attributable risk and population attributable risk
Attributable risk and population attributable riskAttributable risk and population attributable risk
Attributable risk and population attributable risk
 
Targeted therapy and immunotherapy in lung cancer
Targeted therapy and immunotherapy in lung cancerTargeted therapy and immunotherapy in lung cancer
Targeted therapy and immunotherapy in lung cancer
 
Efficacy endpoints in Oncology
Efficacy endpoints in OncologyEfficacy endpoints in Oncology
Efficacy endpoints in Oncology
 
Metaanalysis copy
Metaanalysis    copyMetaanalysis    copy
Metaanalysis copy
 
P value
P valueP value
P value
 
Odds ratios (Basic concepts)
Odds ratios (Basic concepts)Odds ratios (Basic concepts)
Odds ratios (Basic concepts)
 
Medical Statistics used in Oncology
Medical Statistics used in OncologyMedical Statistics used in Oncology
Medical Statistics used in Oncology
 
Noninferiority Trials Presentation
Noninferiority Trials PresentationNoninferiority Trials Presentation
Noninferiority Trials Presentation
 
Cohort study - basics
Cohort study - basicsCohort study - basics
Cohort study - basics
 

Destacado

Destacado (9)

Bortezomib as standard of care for multiple myeloma
Bortezomib as standard of care for multiple myelomaBortezomib as standard of care for multiple myeloma
Bortezomib as standard of care for multiple myeloma
 
Proteasome inhibitors in treatment of multiple myeloma
Proteasome inhibitors in treatment of multiple myelomaProteasome inhibitors in treatment of multiple myeloma
Proteasome inhibitors in treatment of multiple myeloma
 
Doxil (doxorubicin)
Doxil (doxorubicin)Doxil (doxorubicin)
Doxil (doxorubicin)
 
Liposom
LiposomLiposom
Liposom
 
Multiple Myeloma
Multiple MyelomaMultiple Myeloma
Multiple Myeloma
 
Zydus cadila
Zydus cadilaZydus cadila
Zydus cadila
 
Zydus
ZydusZydus
Zydus
 
Ovarian cancer ppt
Ovarian cancer pptOvarian cancer ppt
Ovarian cancer ppt
 
Liposomes
LiposomesLiposomes
Liposomes
 

Similar a Hazard ratios

Understanding the evidence in pharmacoepidemiology study
Understanding the evidence in pharmacoepidemiology studyUnderstanding the evidence in pharmacoepidemiology study
Understanding the evidence in pharmacoepidemiology studykamolwantnok
 
Clinical trial study design
Clinical trial study designClinical trial study design
Clinical trial study designNermin Osman
 
Measuring the Potential Impact of Frailty on the Apparent Declining Efficacy ...
Measuring the Potential Impact of Frailty on the Apparent Declining Efficacy ...Measuring the Potential Impact of Frailty on the Apparent Declining Efficacy ...
Measuring the Potential Impact of Frailty on the Apparent Declining Efficacy ...fhardnett
 
Quantifying the process of empathy during crisis interventions
Quantifying the process of empathy during crisis interventionsQuantifying the process of empathy during crisis interventions
Quantifying the process of empathy during crisis interventionsCraig Bryan
 
statistical methods in epidemiology.pptx
statistical methods in epidemiology.pptxstatistical methods in epidemiology.pptx
statistical methods in epidemiology.pptxAnusha Are
 
Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...
Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...
Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...Dr. Aryan (Anish Dhakal)
 
Measurement of epidemiology.pptx
Measurement of epidemiology.pptxMeasurement of epidemiology.pptx
Measurement of epidemiology.pptxradha maharjan
 
Important definitions in statistics
Important definitions in statistics Important definitions in statistics
Important definitions in statistics Aboubakr Elnashar
 
Estimating risk ,pptx
Estimating risk ,pptxEstimating risk ,pptx
Estimating risk ,pptxsoudfaiza
 
Case control study - Part 2
Case control study - Part 2Case control study - Part 2
Case control study - Part 2Rizwan S A
 
Tom kelly genetics journal club 2016
Tom kelly   genetics journal club 2016Tom kelly   genetics journal club 2016
Tom kelly genetics journal club 2016Tom Kelly
 
Choosing appropriate statistical test RSS6 2104
Choosing appropriate statistical test RSS6 2104Choosing appropriate statistical test RSS6 2104
Choosing appropriate statistical test RSS6 2104RSS6
 
Mey Akashah "Risk Assessment," Harvard
Mey Akashah "Risk Assessment," HarvardMey Akashah "Risk Assessment," Harvard
Mey Akashah "Risk Assessment," HarvardMey Akashah
 
Cross sectional studies
Cross sectional studiesCross sectional studies
Cross sectional studiessoudfaiza
 
Mesures of Disease Association (1).ppt
Mesures of Disease Association (1).pptMesures of Disease Association (1).ppt
Mesures of Disease Association (1).pptchcjayanagara
 

Similar a Hazard ratios (20)

Understanding the evidence in pharmacoepidemiology study
Understanding the evidence in pharmacoepidemiology studyUnderstanding the evidence in pharmacoepidemiology study
Understanding the evidence in pharmacoepidemiology study
 
Clinical trial study design
Clinical trial study designClinical trial study design
Clinical trial study design
 
Measuring the Potential Impact of Frailty on the Apparent Declining Efficacy ...
Measuring the Potential Impact of Frailty on the Apparent Declining Efficacy ...Measuring the Potential Impact of Frailty on the Apparent Declining Efficacy ...
Measuring the Potential Impact of Frailty on the Apparent Declining Efficacy ...
 
Epidemiology v1.3 unit 3
Epidemiology v1.3 unit 3Epidemiology v1.3 unit 3
Epidemiology v1.3 unit 3
 
Concept f risk
Concept f riskConcept f risk
Concept f risk
 
Risk Comparison
Risk ComparisonRisk Comparison
Risk Comparison
 
Quantifying the process of empathy during crisis interventions
Quantifying the process of empathy during crisis interventionsQuantifying the process of empathy during crisis interventions
Quantifying the process of empathy during crisis interventions
 
statistical methods in epidemiology.pptx
statistical methods in epidemiology.pptxstatistical methods in epidemiology.pptx
statistical methods in epidemiology.pptx
 
Evidence-Based Medicine Glossary
Evidence-Based Medicine GlossaryEvidence-Based Medicine Glossary
Evidence-Based Medicine Glossary
 
Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...
Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...
Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...
 
Measurement of epidemiology.pptx
Measurement of epidemiology.pptxMeasurement of epidemiology.pptx
Measurement of epidemiology.pptx
 
Important definitions in statistics
Important definitions in statistics Important definitions in statistics
Important definitions in statistics
 
Estimating risk ,pptx
Estimating risk ,pptxEstimating risk ,pptx
Estimating risk ,pptx
 
Case control study - Part 2
Case control study - Part 2Case control study - Part 2
Case control study - Part 2
 
Tom kelly genetics journal club 2016
Tom kelly   genetics journal club 2016Tom kelly   genetics journal club 2016
Tom kelly genetics journal club 2016
 
Choosing appropriate statistical test RSS6 2104
Choosing appropriate statistical test RSS6 2104Choosing appropriate statistical test RSS6 2104
Choosing appropriate statistical test RSS6 2104
 
Epidemic presention
Epidemic presentionEpidemic presention
Epidemic presention
 
Mey Akashah "Risk Assessment," Harvard
Mey Akashah "Risk Assessment," HarvardMey Akashah "Risk Assessment," Harvard
Mey Akashah "Risk Assessment," Harvard
 
Cross sectional studies
Cross sectional studiesCross sectional studies
Cross sectional studies
 
Mesures of Disease Association (1).ppt
Mesures of Disease Association (1).pptMesures of Disease Association (1).ppt
Mesures of Disease Association (1).ppt
 

Más de Terry Shaneyfelt

Blinding in Clinical Trials
Blinding in Clinical TrialsBlinding in Clinical Trials
Blinding in Clinical TrialsTerry Shaneyfelt
 
Real vs rubbish ebm Evidence Live presentation april 2015
Real vs rubbish ebm  Evidence Live presentation april 2015Real vs rubbish ebm  Evidence Live presentation april 2015
Real vs rubbish ebm Evidence Live presentation april 2015Terry Shaneyfelt
 
Preoperative assessment of the older patient
Preoperative assessment of the older patientPreoperative assessment of the older patient
Preoperative assessment of the older patientTerry Shaneyfelt
 
UAB Pulmonary board review study design and statistical principles
UAB Pulmonary board review study  design and statistical principles UAB Pulmonary board review study  design and statistical principles
UAB Pulmonary board review study design and statistical principles Terry Shaneyfelt
 
Perioperative management of patients on corticosteroids
Perioperative management of patients on corticosteroidsPerioperative management of patients on corticosteroids
Perioperative management of patients on corticosteroidsTerry Shaneyfelt
 
Perioperative Management of Hypothyroid Patients Undergoing Nonthyroidal Surgery
Perioperative Management of Hypothyroid Patients Undergoing Nonthyroidal SurgeryPerioperative Management of Hypothyroid Patients Undergoing Nonthyroidal Surgery
Perioperative Management of Hypothyroid Patients Undergoing Nonthyroidal SurgeryTerry Shaneyfelt
 
Perioperative Diabetes Management in Patients on Insulin
Perioperative Diabetes Management in Patients on InsulinPerioperative Diabetes Management in Patients on Insulin
Perioperative Diabetes Management in Patients on InsulinTerry Shaneyfelt
 
Glycemia management in patients on oral agents
Glycemia management in patients on oral agentsGlycemia management in patients on oral agents
Glycemia management in patients on oral agentsTerry Shaneyfelt
 
Preoperative evaluation of patients with diabetes
Preoperative evaluation of patients with diabetesPreoperative evaluation of patients with diabetes
Preoperative evaluation of patients with diabetesTerry Shaneyfelt
 
Preoperative evaluation of adults with sleep apnea
Preoperative evaluation of adults with sleep apneaPreoperative evaluation of adults with sleep apnea
Preoperative evaluation of adults with sleep apneaTerry Shaneyfelt
 
Strategies to reduce postoperative pulmonary complications
Strategies to reduce postoperative pulmonary complicationsStrategies to reduce postoperative pulmonary complications
Strategies to reduce postoperative pulmonary complicationsTerry Shaneyfelt
 
Who needs preoperative pulmonary testing prior to noncardiothoracic surgery?
Who needs preoperative pulmonary testing prior to noncardiothoracic surgery?Who needs preoperative pulmonary testing prior to noncardiothoracic surgery?
Who needs preoperative pulmonary testing prior to noncardiothoracic surgery?Terry Shaneyfelt
 
Gupta indices for postop pulmonary complications
Gupta indices for postop pulmonary complicationsGupta indices for postop pulmonary complications
Gupta indices for postop pulmonary complicationsTerry Shaneyfelt
 
Procedure related risk factors for postop pulmonary complications
Procedure related risk factors for postop pulmonary complicationsProcedure related risk factors for postop pulmonary complications
Procedure related risk factors for postop pulmonary complicationsTerry Shaneyfelt
 
Patient related risk factors for postop pulmonary complications
Patient related risk factors for postop pulmonary complicationsPatient related risk factors for postop pulmonary complications
Patient related risk factors for postop pulmonary complicationsTerry Shaneyfelt
 
Noncardiac Surgery After PCI
Noncardiac Surgery After PCINoncardiac Surgery After PCI
Noncardiac Surgery After PCITerry Shaneyfelt
 
Reducing Perioperative Cardiac Risk: Do Beta blockers Help?
Reducing Perioperative Cardiac Risk: Do Beta blockers Help?Reducing Perioperative Cardiac Risk: Do Beta blockers Help?
Reducing Perioperative Cardiac Risk: Do Beta blockers Help?Terry Shaneyfelt
 
Reducing perioperative cardiac complications: statins
Reducing perioperative cardiac complications: statinsReducing perioperative cardiac complications: statins
Reducing perioperative cardiac complications: statinsTerry Shaneyfelt
 
Who needs preoperative noninvasive cardiac testing
Who needs preoperative noninvasive cardiac testingWho needs preoperative noninvasive cardiac testing
Who needs preoperative noninvasive cardiac testingTerry Shaneyfelt
 
Comparison of cardiac preoperative risk prediction indices
Comparison of cardiac preoperative risk prediction indicesComparison of cardiac preoperative risk prediction indices
Comparison of cardiac preoperative risk prediction indicesTerry Shaneyfelt
 

Más de Terry Shaneyfelt (20)

Blinding in Clinical Trials
Blinding in Clinical TrialsBlinding in Clinical Trials
Blinding in Clinical Trials
 
Real vs rubbish ebm Evidence Live presentation april 2015
Real vs rubbish ebm  Evidence Live presentation april 2015Real vs rubbish ebm  Evidence Live presentation april 2015
Real vs rubbish ebm Evidence Live presentation april 2015
 
Preoperative assessment of the older patient
Preoperative assessment of the older patientPreoperative assessment of the older patient
Preoperative assessment of the older patient
 
UAB Pulmonary board review study design and statistical principles
UAB Pulmonary board review study  design and statistical principles UAB Pulmonary board review study  design and statistical principles
UAB Pulmonary board review study design and statistical principles
 
Perioperative management of patients on corticosteroids
Perioperative management of patients on corticosteroidsPerioperative management of patients on corticosteroids
Perioperative management of patients on corticosteroids
 
Perioperative Management of Hypothyroid Patients Undergoing Nonthyroidal Surgery
Perioperative Management of Hypothyroid Patients Undergoing Nonthyroidal SurgeryPerioperative Management of Hypothyroid Patients Undergoing Nonthyroidal Surgery
Perioperative Management of Hypothyroid Patients Undergoing Nonthyroidal Surgery
 
Perioperative Diabetes Management in Patients on Insulin
Perioperative Diabetes Management in Patients on InsulinPerioperative Diabetes Management in Patients on Insulin
Perioperative Diabetes Management in Patients on Insulin
 
Glycemia management in patients on oral agents
Glycemia management in patients on oral agentsGlycemia management in patients on oral agents
Glycemia management in patients on oral agents
 
Preoperative evaluation of patients with diabetes
Preoperative evaluation of patients with diabetesPreoperative evaluation of patients with diabetes
Preoperative evaluation of patients with diabetes
 
Preoperative evaluation of adults with sleep apnea
Preoperative evaluation of adults with sleep apneaPreoperative evaluation of adults with sleep apnea
Preoperative evaluation of adults with sleep apnea
 
Strategies to reduce postoperative pulmonary complications
Strategies to reduce postoperative pulmonary complicationsStrategies to reduce postoperative pulmonary complications
Strategies to reduce postoperative pulmonary complications
 
Who needs preoperative pulmonary testing prior to noncardiothoracic surgery?
Who needs preoperative pulmonary testing prior to noncardiothoracic surgery?Who needs preoperative pulmonary testing prior to noncardiothoracic surgery?
Who needs preoperative pulmonary testing prior to noncardiothoracic surgery?
 
Gupta indices for postop pulmonary complications
Gupta indices for postop pulmonary complicationsGupta indices for postop pulmonary complications
Gupta indices for postop pulmonary complications
 
Procedure related risk factors for postop pulmonary complications
Procedure related risk factors for postop pulmonary complicationsProcedure related risk factors for postop pulmonary complications
Procedure related risk factors for postop pulmonary complications
 
Patient related risk factors for postop pulmonary complications
Patient related risk factors for postop pulmonary complicationsPatient related risk factors for postop pulmonary complications
Patient related risk factors for postop pulmonary complications
 
Noncardiac Surgery After PCI
Noncardiac Surgery After PCINoncardiac Surgery After PCI
Noncardiac Surgery After PCI
 
Reducing Perioperative Cardiac Risk: Do Beta blockers Help?
Reducing Perioperative Cardiac Risk: Do Beta blockers Help?Reducing Perioperative Cardiac Risk: Do Beta blockers Help?
Reducing Perioperative Cardiac Risk: Do Beta blockers Help?
 
Reducing perioperative cardiac complications: statins
Reducing perioperative cardiac complications: statinsReducing perioperative cardiac complications: statins
Reducing perioperative cardiac complications: statins
 
Who needs preoperative noninvasive cardiac testing
Who needs preoperative noninvasive cardiac testingWho needs preoperative noninvasive cardiac testing
Who needs preoperative noninvasive cardiac testing
 
Comparison of cardiac preoperative risk prediction indices
Comparison of cardiac preoperative risk prediction indicesComparison of cardiac preoperative risk prediction indices
Comparison of cardiac preoperative risk prediction indices
 

Último

Carero dropshipping via API with DroFx.pptx
Carero dropshipping via API with DroFx.pptxCarero dropshipping via API with DroFx.pptx
Carero dropshipping via API with DroFx.pptxolyaivanovalion
 
Schema on read is obsolete. Welcome metaprogramming..pdf
Schema on read is obsolete. Welcome metaprogramming..pdfSchema on read is obsolete. Welcome metaprogramming..pdf
Schema on read is obsolete. Welcome metaprogramming..pdfLars Albertsson
 
Ravak dropshipping via API with DroFx.pptx
Ravak dropshipping via API with DroFx.pptxRavak dropshipping via API with DroFx.pptx
Ravak dropshipping via API with DroFx.pptxolyaivanovalion
 
Smarteg dropshipping via API with DroFx.pptx
Smarteg dropshipping via API with DroFx.pptxSmarteg dropshipping via API with DroFx.pptx
Smarteg dropshipping via API with DroFx.pptxolyaivanovalion
 
Call Girls Hsr Layout Just Call 👗 7737669865 👗 Top Class Call Girl Service Ba...
Call Girls Hsr Layout Just Call 👗 7737669865 👗 Top Class Call Girl Service Ba...Call Girls Hsr Layout Just Call 👗 7737669865 👗 Top Class Call Girl Service Ba...
Call Girls Hsr Layout Just Call 👗 7737669865 👗 Top Class Call Girl Service Ba...amitlee9823
 
Best VIP Call Girls Noida Sector 22 Call Me: 8448380779
Best VIP Call Girls Noida Sector 22 Call Me: 8448380779Best VIP Call Girls Noida Sector 22 Call Me: 8448380779
Best VIP Call Girls Noida Sector 22 Call Me: 8448380779Delhi Call girls
 
Vip Model Call Girls (Delhi) Karol Bagh 9711199171✔️Body to body massage wit...
Vip Model  Call Girls (Delhi) Karol Bagh 9711199171✔️Body to body massage wit...Vip Model  Call Girls (Delhi) Karol Bagh 9711199171✔️Body to body massage wit...
Vip Model Call Girls (Delhi) Karol Bagh 9711199171✔️Body to body massage wit...shivangimorya083
 
Cheap Rate Call girls Sarita Vihar Delhi 9205541914 shot 1500 night
Cheap Rate Call girls Sarita Vihar Delhi 9205541914 shot 1500 nightCheap Rate Call girls Sarita Vihar Delhi 9205541914 shot 1500 night
Cheap Rate Call girls Sarita Vihar Delhi 9205541914 shot 1500 nightDelhi Call girls
 
Halmar dropshipping via API with DroFx
Halmar  dropshipping  via API with DroFxHalmar  dropshipping  via API with DroFx
Halmar dropshipping via API with DroFxolyaivanovalion
 
Mature dropshipping via API with DroFx.pptx
Mature dropshipping via API with DroFx.pptxMature dropshipping via API with DroFx.pptx
Mature dropshipping via API with DroFx.pptxolyaivanovalion
 
FESE Capital Markets Fact Sheet 2024 Q1.pdf
FESE Capital Markets Fact Sheet 2024 Q1.pdfFESE Capital Markets Fact Sheet 2024 Q1.pdf
FESE Capital Markets Fact Sheet 2024 Q1.pdfMarinCaroMartnezBerg
 
Delhi Call Girls Punjabi Bagh 9711199171 ☎✔👌✔ Whatsapp Hard And Sexy Vip Call
Delhi Call Girls Punjabi Bagh 9711199171 ☎✔👌✔ Whatsapp Hard And Sexy Vip CallDelhi Call Girls Punjabi Bagh 9711199171 ☎✔👌✔ Whatsapp Hard And Sexy Vip Call
Delhi Call Girls Punjabi Bagh 9711199171 ☎✔👌✔ Whatsapp Hard And Sexy Vip Callshivangimorya083
 
BigBuy dropshipping via API with DroFx.pptx
BigBuy dropshipping via API with DroFx.pptxBigBuy dropshipping via API with DroFx.pptx
BigBuy dropshipping via API with DroFx.pptxolyaivanovalion
 
Edukaciniai dropshipping via API with DroFx
Edukaciniai dropshipping via API with DroFxEdukaciniai dropshipping via API with DroFx
Edukaciniai dropshipping via API with DroFxolyaivanovalion
 
BPAC WITH UFSBI GENERAL PRESENTATION 18_05_2017-1.pptx
BPAC WITH UFSBI GENERAL PRESENTATION 18_05_2017-1.pptxBPAC WITH UFSBI GENERAL PRESENTATION 18_05_2017-1.pptx
BPAC WITH UFSBI GENERAL PRESENTATION 18_05_2017-1.pptxMohammedJunaid861692
 
Generative AI on Enterprise Cloud with NiFi and Milvus
Generative AI on Enterprise Cloud with NiFi and MilvusGenerative AI on Enterprise Cloud with NiFi and Milvus
Generative AI on Enterprise Cloud with NiFi and MilvusTimothy Spann
 
VidaXL dropshipping via API with DroFx.pptx
VidaXL dropshipping via API with DroFx.pptxVidaXL dropshipping via API with DroFx.pptx
VidaXL dropshipping via API with DroFx.pptxolyaivanovalion
 

Último (20)

Carero dropshipping via API with DroFx.pptx
Carero dropshipping via API with DroFx.pptxCarero dropshipping via API with DroFx.pptx
Carero dropshipping via API with DroFx.pptx
 
Schema on read is obsolete. Welcome metaprogramming..pdf
Schema on read is obsolete. Welcome metaprogramming..pdfSchema on read is obsolete. Welcome metaprogramming..pdf
Schema on read is obsolete. Welcome metaprogramming..pdf
 
Ravak dropshipping via API with DroFx.pptx
Ravak dropshipping via API with DroFx.pptxRavak dropshipping via API with DroFx.pptx
Ravak dropshipping via API with DroFx.pptx
 
Smarteg dropshipping via API with DroFx.pptx
Smarteg dropshipping via API with DroFx.pptxSmarteg dropshipping via API with DroFx.pptx
Smarteg dropshipping via API with DroFx.pptx
 
Sampling (random) method and Non random.ppt
Sampling (random) method and Non random.pptSampling (random) method and Non random.ppt
Sampling (random) method and Non random.ppt
 
Delhi 99530 vip 56974 Genuine Escort Service Call Girls in Kishangarh
Delhi 99530 vip 56974 Genuine Escort Service Call Girls in  KishangarhDelhi 99530 vip 56974 Genuine Escort Service Call Girls in  Kishangarh
Delhi 99530 vip 56974 Genuine Escort Service Call Girls in Kishangarh
 
Abortion pills in Doha Qatar (+966572737505 ! Get Cytotec
Abortion pills in Doha Qatar (+966572737505 ! Get CytotecAbortion pills in Doha Qatar (+966572737505 ! Get Cytotec
Abortion pills in Doha Qatar (+966572737505 ! Get Cytotec
 
Call Girls Hsr Layout Just Call 👗 7737669865 👗 Top Class Call Girl Service Ba...
Call Girls Hsr Layout Just Call 👗 7737669865 👗 Top Class Call Girl Service Ba...Call Girls Hsr Layout Just Call 👗 7737669865 👗 Top Class Call Girl Service Ba...
Call Girls Hsr Layout Just Call 👗 7737669865 👗 Top Class Call Girl Service Ba...
 
Best VIP Call Girls Noida Sector 22 Call Me: 8448380779
Best VIP Call Girls Noida Sector 22 Call Me: 8448380779Best VIP Call Girls Noida Sector 22 Call Me: 8448380779
Best VIP Call Girls Noida Sector 22 Call Me: 8448380779
 
Vip Model Call Girls (Delhi) Karol Bagh 9711199171✔️Body to body massage wit...
Vip Model  Call Girls (Delhi) Karol Bagh 9711199171✔️Body to body massage wit...Vip Model  Call Girls (Delhi) Karol Bagh 9711199171✔️Body to body massage wit...
Vip Model Call Girls (Delhi) Karol Bagh 9711199171✔️Body to body massage wit...
 
Cheap Rate Call girls Sarita Vihar Delhi 9205541914 shot 1500 night
Cheap Rate Call girls Sarita Vihar Delhi 9205541914 shot 1500 nightCheap Rate Call girls Sarita Vihar Delhi 9205541914 shot 1500 night
Cheap Rate Call girls Sarita Vihar Delhi 9205541914 shot 1500 night
 
Halmar dropshipping via API with DroFx
Halmar  dropshipping  via API with DroFxHalmar  dropshipping  via API with DroFx
Halmar dropshipping via API with DroFx
 
Mature dropshipping via API with DroFx.pptx
Mature dropshipping via API with DroFx.pptxMature dropshipping via API with DroFx.pptx
Mature dropshipping via API with DroFx.pptx
 
FESE Capital Markets Fact Sheet 2024 Q1.pdf
FESE Capital Markets Fact Sheet 2024 Q1.pdfFESE Capital Markets Fact Sheet 2024 Q1.pdf
FESE Capital Markets Fact Sheet 2024 Q1.pdf
 
Delhi Call Girls Punjabi Bagh 9711199171 ☎✔👌✔ Whatsapp Hard And Sexy Vip Call
Delhi Call Girls Punjabi Bagh 9711199171 ☎✔👌✔ Whatsapp Hard And Sexy Vip CallDelhi Call Girls Punjabi Bagh 9711199171 ☎✔👌✔ Whatsapp Hard And Sexy Vip Call
Delhi Call Girls Punjabi Bagh 9711199171 ☎✔👌✔ Whatsapp Hard And Sexy Vip Call
 
BigBuy dropshipping via API with DroFx.pptx
BigBuy dropshipping via API with DroFx.pptxBigBuy dropshipping via API with DroFx.pptx
BigBuy dropshipping via API with DroFx.pptx
 
Edukaciniai dropshipping via API with DroFx
Edukaciniai dropshipping via API with DroFxEdukaciniai dropshipping via API with DroFx
Edukaciniai dropshipping via API with DroFx
 
BPAC WITH UFSBI GENERAL PRESENTATION 18_05_2017-1.pptx
BPAC WITH UFSBI GENERAL PRESENTATION 18_05_2017-1.pptxBPAC WITH UFSBI GENERAL PRESENTATION 18_05_2017-1.pptx
BPAC WITH UFSBI GENERAL PRESENTATION 18_05_2017-1.pptx
 
Generative AI on Enterprise Cloud with NiFi and Milvus
Generative AI on Enterprise Cloud with NiFi and MilvusGenerative AI on Enterprise Cloud with NiFi and Milvus
Generative AI on Enterprise Cloud with NiFi and Milvus
 
VidaXL dropshipping via API with DroFx.pptx
VidaXL dropshipping via API with DroFx.pptxVidaXL dropshipping via API with DroFx.pptx
VidaXL dropshipping via API with DroFx.pptx
 

Hazard ratios

  • 1. Interpreting Hazard Ratios Terry Shaneyfelt, MD, MPH Associate Professor of Medicine UAB Department of Medicine ebmteacher.com
  • 2. • Time-to-event analysis • Ratio of hazards • Hazard – Instantaneous event rate • Probability that an individual at time t has an event at that time (assuming event-free survival to time t) Hazard Ratio Hazard in treatment arm Hazard in control arm HR=
  • 3. • HR = 1 (event rates are the same in both arms) • HR = 2 (at any time twice as many patients in the treatment group are having an event proportionally to the comparator group) • HR = 0.5 (at an time half as many patients in the treatment group are having an event proportionally to the comparator group) Interpreting Hazard Ratios
  • 4. • Often interpreted as a relative risk – Not technically the same Interpreting Hazard Ratios http://cancerguide.org/scurve_basic.html Lancet 2003;361:1149

Notas del editor

  1. Disclaimer- this is intended for nonstatisticians. If you are looking for fancy formulas depicting hazards you have come to the wrong place.
  2. Hazard ratios are used when studies measure time to events- from enrollment in the study to some outcome. For example, disease free survival, time to relapse, etc. This is called survival analysis. Hazard ratios are just a ratio of hazards with the hazard in the treatment arm divided by the hazard in the control arm. A hazard is an instantaneous event rate. It’s the risk of an event happening at a particular time (assuming the patient hasn’t experienced the event up to that time).
  3. This is a graph of the primary outcome (nonfatal MI and fatal CHD) in the ASCOT-LLA trial. The reference at the bottom of the slide is a website describing how to interpret survival curves (which is depicted here). Outcomes are measured over time from enrollment in the study (year 0 at the bottom) to development of the outcome or ending of the study (year 3.5). The solid black line represents outcomes accruing over time in the atorvastatin patients and the dotted line that in the placebo assigned patients. The hazard ratio (HR) derived from a cox proportional hazards model is 0.64. What does this mean? It means at any given time patients assigned to atorvastatin are 36% less likely to experience the primary outcome than those assigned to placebo (assuming they haven't experienced the outcome already). This is in contrast to a relative risk which is usually measured at the end of a trial and would be interpreted as those assigned to atorvastin experienced 36% less outcomes relative to placebo. A subtle difference but an important one.